Transmission of HIV-1 in the face of neutralizing antibodies

Current HIV Research

Volumn 5, Issue 6, 2007, Pages 578-587

  Blish, Catherine A ^a   Blay, Wendy M ^b   Haigwood, Nancy L ^b   Overbaugh, Julie ^a  

^a USA   (United States)

^b SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

HIV 1; Monoclonal antibodies; Mother to child transmission; Neutralizing antibodies; Superinfection; Transmission

Indexed keywords

MATERNAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGENICITY; DRUG DEVELOPMENT; DRUG SENSITIVITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INCIDENCE; INFECTION PREVENTION; INFECTION RESISTANCE; INFECTION RISK; NONHUMAN; REVIEW; SEXUAL TRANSMISSION; SUPERINFECTION; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ANTIBODIES, MONOCLONAL; DISEASE TRANSMISSION, HORIZONTAL; DISEASE TRANSMISSION, VERTICAL; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; VIRAL LOAD;

EID: 38949141652     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016207782418461     Document Type: Review

References (116)

1. Ahmad N, Baroudy BM, Baker RC, Chappey C. (1995). Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission. Journal of Virology. 69: 1001-1012.
2. Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, Montefiori DC, O'Connor DH, Davis BT, Lee PK, Maier EL, Harlow J, Goulder PJ, Brander C, Rosenberg ES, Walker BD. (2002). HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature. 420: 434-439.
3. Barbas CF, 3rd, Bjorling E, Chiodi F, Dunlop N, Cababa D, Jones TM, Zebedee SL, Persson MA, Nara PL, Norrby E. (1992). Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proceedings of the National Academy of Sciences of the United States of America. 89: 9339-9343.
4. Barin F, Jourdain G, Brunet S, Ngo-Giang-Huong N, Weerawatgoompa S, Kamchanamayul W, Ariyadej S, Hansudewechakul R, Achalapong J, Yuthavisuthi P, Ngampiyaskul C, Bhakeecheep S, Hemwutthiphan C, Lallemant M. (2006). Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1. Journal of Infectious Diseases. 193: 1504-1511.
5. Becquart P, Hocini H, Levy M, Sepou A, Kazatchkine MD, Belec L. (2000). Secretory anti-human immunodeficiency virus (HIV) antibodies in colostrum and breast milk are not a major determinant of the protection of early postnatal transmission of HIV. Journal of Infectious Diseases. 181: 532-539.
6. Belec L, Bouquety JC, Georges AJ, Siopathis MR, Martin PM. (1990). Antibodies to human immunodeficiency virus in the breast milk of healthy, seropositive women. Pediatrics. 85: 1022-1026.
7. Belec L, Ghys PD, Hocini H, Nkengasong JN, Tranchot-Diallo J, Diallo MO, Ettiegne-Traore V, Maurice C, Becquart P, Matta M, Si-Mohamed A, Chomont N, Coulibaly IM, Wiktor SZ, Kazatehkine MD. (2001). Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. Journal of Infectious Diseases. 184: 1412-1422.
8. Beyrer C, Artenstein AW, Rugpao S, Stephens H, VanCott TC, Robb ML, Rinkaew M, Birx DL, Khamboonruang C, Zimmerman PA, Nelson KE, Natpratan C. (1999). Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group. Journal of Infectious Diseases. 179: 59-67.
9. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR. (2004). Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. Journal of Virology. 78: 13232-13252.
10. Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J. (2007). HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS. 21: 693-702.
11. Bongertz V, Costa CI, Veloso VG, Grinsztejn B, Joao Filho EC, Calvet G, Pilotto JH, Guimaraes ML, Morgado MG. (2001). Vertical HIV-1 transmission: importance of neutralizing antibody titer and specificity. Scandinavian Journal of Immunology. 53: 302-309.
12. Brenner B, Routy JP, Quan Y, Moisi D, Oliveira M, Turner D, Wainberg MA. (2004). Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS. 18: 1653-1660.
13. Briant L, Wade CM, Puel J, Brown AJ, Guyader M. (1995). Analysis of envelope sequence variants suggests multiple mechanisms of mother-to-child transmission of human immunodeficiency virus type 1. Journal of Virology. 69: 3778-3788.
14. Broliden K, Hinkula J, Devito C, Kiama P, Kimani J, Trabbatoni D, Bwayo JJ, Clerici M, Plummer F, Kaul R. (2001). Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunology Letters. 79: 29-36.
15. Brown SA, Hurwitz JL, Zhan X, Doherty PC, Slobod KS. (2005). CD8+ T-cells: are they sufficient to prevent, contain or eradicate HIV-1 infection? Current Drug Targets: Infectious Disorders. 5: 113-119.
16. Buchacz K, Parekh BS, Padian NS, van der Straten A, Phillips S, Jonte J, Holmberg SD. (2001). HIV-specific IgG in cervicovaginal secretions of exposed HIV-uninfected female sexual partners of HIV-infected men. AIDS Research and Human Retroviruses. 17: 1689-1693.
17. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL. (1994). Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 266: 1024-1027.
18. Calarota SA, Libonatti OV. (2000). Maternal antibodies to HIV-1 envelope domains: No correlation with HIV-1 vertical transmission in patients from Argentina. Scandinavian Journal of Immunology. 52: 292-297.
19. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. (1995). Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. New England Journal of Medicine. 332: 201-208.
20. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, Overbaugh J. (2005). Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. Journal of Virology. 79: 6528-6531.
21. Chohan B, Lavreys L, Rainwater SM, Overbaugh J. (2005). Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. Journal of Virology. 79: 10701-10708.
22. Clerici M, Barassi C, Devito C, Pastori C, Piconi S, Trabattoni D, Longhi R, Hinkula J, Broliden K, Lopalco L. (2002). Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS. 16: 1731-1741.
23. Deeks SG, Schweighardt B, Wrin T, Galovich J, Hoh R, Sinclair E, Hunt P, McCune JM, Martin JN, Petropoulos CJ, Hecht FM. (2006). Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutraliziug antibody responses. Journal of Virology. 80: 6155-6164.
24. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH, Shaw GM, Korber BT, Allen S, Hunter E. (2004). Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science. 303: 2019-2022.
25. Devito C, Hinkula J, Kaul R, Kimani J, Kiama P, Lopalco L, Barras C, Piconi S, Trabattoni D, Bwayo JJ, Plummer F, Clerici M, Broliden K. (2002). Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. Journal of Acquired Immune Deficiency Syndrome 30: 413-420.
26. Dickover R, Garratty E, Yusim K, Miller C, Korber B, Bryson Y. (2006). Role of Maternal Autologous Neutralizing Antibody in Selective Perinatal Transmission of Human Immunodeficiency Virus Type 1 Escape Variants. Journal of Virology. 80: 6525-6533.
27. Dickover RE, Garratty-EM, Plaeger S, Bryson YJ. (2001). Perinatal transmission of major, minor, and multiple maternal hunian immunodeficiency virus type 1 variants in utero and intrapartum. Journal of Virology. 75: 2194-2203.
28. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, Wang T, Xu W, Li PL, Montefiori DC, Cavacini LA, Katinger H. Stiegler G, Anderson DC, McClure HM, Ruprecht RM. (2003). Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS. 117: 301-309.
29. Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Wang T, Montefiori DC, Katinger H, Stiegler G, Anderson DC, McClure HM, Ruprecht RM. (2004). Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. Journal of Infectious Diseases. 189: 2167-2173.
30. Frost SD, Liu Y, Pond SL, Chappey C, Wrin T, Petropoulos CJ, Little SJ, Richman DD. (2005). Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. Journal of Virology. 79: 6523-6527.
31. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, Paxinos E, Chappey C, Galovich J, Beauchaine J, Petropoulos CJ, Little SJ, Richman DD. (2005). Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proceedings of the National Academy of Sciences of the United States of America. 102: 18514-18519.
32. Gonzales MJ, Delwart E, Rhee SY, Tsui R, Zolopa AR, Taylor J, Shafer RW. (2003). Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. Journal of Infectious Diseases. 188: 397-405.
33. Gottlieb GS, Nickle DC, Jensen MA, Wong KG, Grobler J, Li F, Liu SL, Rademeyer C, Learn GH, Karim SS, Williamson C, Corey L, Margolick JB, Mullins JI. (2004). Dual HIV-1 infection associated with rapid disease progression. Lancet. 363: 619-622.
34. Gray ES, Meyers T, Gray G, Montefiori DC, Morris L. (2006) Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralining monoclonal antibodies raised against subtype B. PLoS Medicine. 3: e255.
35. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, Karim SS, Williamson C, Morris L. (2007). Neutralizing antibody responses in acute human immunodeficiency virus type-1 subtype C infection. Journal of Virology. 81: 6187-6196.
36. Grobler J, Gray CM, Rademeyer C, Seoighe C, Ramjee G, Karim SA, Morris L, Williamson C. (2004). Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. Journal of Infectious Disease. 190: 1355-1359.
37. Haigwood NL, Montefiori DC, Sutton WF, McClure J, Watson AJ, Voss G, Hirsch VM, Richardson BA, Letvin NL, Hu SL, Johnson PR. (2004). Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. Journal of Virology. 78: 5983-5995.
38. Haigwood NL, Watson A, Sutton WF, McClure J, Lewis A, Ranchalis J, Travis B, Voss G, Letvin NL, Hu SL, Hirsch VM, Johnson PR. (1996). Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunology Letters: 51: 107-114.
39. Herbeck JT, Nickle DC, Learn GH, Gottlieb GS, Curlin ME, Heath L, Mullins JI. (2006). Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host. Journal of Virology. 80: 1637-1644.
40. Hofmann-Lehmann R, Rasmussen RA, Vlasak J, Smith BA, Baba TW, Liska V, Montefiori DC, McClure HM, Anderson DC, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Katinger H, Stiegler G, Posner MR, Cavacini LA, Chou TC, Ruprecht RM. (2001). Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission? Journal of Medical Primatology. 30: 190-196.
41. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, Jiang S, Li PL, Baba TW, Montefiori DC, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Katinger H, Stiegler G, Cavacini LA, Posner MR, Ruprecht RM. (2002). Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. Journal of Medical Primatology. 31: 109-119.
42. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, Smith BA, Baba TW, Liska V, Ferrantelli F, Montefiori DC, McClure HM, Anderson DC, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Katinger H, Stiegler G, Cavacini LA, Posner MR, Chou TC, Andersen J, Ruprecht RM. (2001). Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. Journal of Virology. 75: 7470-7480.
43. Innocenti-Francillard P, Brengel-Pesce K, Morand P, Ounanian-Paraz A, Leclercq P, Gruters R, Seigneurin JM. (1997). HIV-1 primary infection in two pairs of patients: difference in variants transmitted and clinical follow-up. AIDS. 11: 539-542.
44. Jansson M, Wahren B, Scarlatti G, Principi N. Lombardi V, Livadiotti S, Elia L, Plebani A, Wigzell H, Rossi P. (1992). Patterns of immunoglobulin G subclass reactivity to HIV-1 envelope peptides in children born to HIV-1-infected mothers. AIDS. 6: 365-371.
45. Jayaraman P, Zhu T, Misher L, Mohan D, Kuller L, Polacino P, Richardson BA, Bielefeldt-Ohmann H, Anderson D, Hu SL, Haigwood NL. (2007). Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3. Journal of Virology. 81: 822-834.
46. Jost S, Bernard MC, Kaiser L. Yerly S, Hirschel B, Samri A, Autran B, Goh LE, Perrin L. (2002). A patient with HIV-1 superinfection. New England Journal of Medicine. 347: 731-736.
47. Kampinga GA, Simonon A, Van de Perre P, Karita E, Msellati P, Goudsmit J. (1997). Primary infections with HIV-1 of women and their offspring in Rwanda: findings of heterogeneity at seroconversion, coinfection, and recombinants of HIV-1 subtypes A and C. Virology. 227: 63-76.
48. Kaul R, Trabattoni D, Bwayo JJ, Arienti D, Zagliani A, Mwangi FM, Kariuki C, Ngugi EN, MacDonald KS, Ball TB, Clerici M, Plummer FA. (1999). HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS. 13: 23-29.
49. Kliks SC, Wara DW, Landers DV, Levy JA. (1994). Features of HIV-1 that could influence maternal-child transmission. JAMA. 272: 467-474.
50. Koelsch KK, Smith DM, Little SJ, Ignacio CC, Macaranas TR, Brown AJ, Petropoulos CJ, Richman DD, Wong JK. (2003). Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. AIDS. 17: F11-16.
51. Kollmann TR, Rubinstein A, Lyman WD, Soeiro R, Goldstein H. (1991). Characterization of IgG and IgG subclass antibodies present in paired maternal and fetal serum which are directed against HIV-1 proteins. AIDS Research and Human Retroviruses. 7: 847-854.
52. Kostrikis LG, Cao Y, Ngai H, Moore JP, Ho DD. (1996). Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. Journal of Virology. 70: 445-458.
53. Kuhn L, Trabattoni D, Kankasa C. Sinkala M, Lissoni F, Ghosh M, Aldrovandi G, Thea D, Clerici M. (2006). Hiv-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants. Journal of Pediatrics. 149: 611-616.
54. Kulkarni PS, Butera ST, Duerr AC. (2003). Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. AIDS Reviews. 5: 87-103.
55. Lamers SL, Sleasman JW, She JX, Barrie KA, Pomeroy SM, Barrett DJ, Goodenow MM. (1994). Persistence of multiple maternal genotypes of human immunodeficiency virus type I in infants infected by vertical transmission. Journal or Clinical Investigation. 93: 380-390.
56. Lathey JL, Tsou J, Brinker K, Hsia K, Meyer WA, 3rd, Spector SA. (1999). Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. Journal of Infectious Diseases. 180: 344-350.
57. Learn GH, Muthui D, Brodie SJ, Zhu T, Diem K, Mullins JI, Corey L. (2002). Virus population homogenization following acute human immunodeficiency virus type 1 infection. Journal of Virology. 76: 11953-11959.
58. Li B, Decker JM, Johnson RW, Bicollet-Ruche F, Wei X, Mulenga J, Allen S, Hunter E, Hahn BH, Shaw GM, Blackwell JL, Derdeyn CA. (2006). Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. Journal of Virology. 80: 5211-5218.
59. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montetori DC. (2005). Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. Journal of Virology. 79: 10108-10125.
60. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, Mlisana K, Karim SA, Hong K, Greene KM, Bilska M, Zhou J, Allen S, Chomba E, Mulenga J, Vwalika C, Gao F, Zhang M, Korber BT, Hunter E, Hahn BH, Montefiori DC. (2006). Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. Journal of Virology. 80: 11776-11790.
61. Lo Caputo S, Trabattoni D, Vichi F, Piconi S, Lopalco L, Villa ML, Mazzotta F, Clerici M. (2003). Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. AIDS. 17: 531-539.
62. Long EM, Martin HL, Jr., Kreiss JK, Rainwater SM, Lavreys L, Jackson DJ, Rakwar J, Mandaliya Y, Overbaugh J. (2000). Gender differences in HIV-1-diversity at time of infection. Nature Medicine. 6: 71-75.
63. Long EM, Rainwater SM, Lavreys L, Mandaliya K, Overbaugh J. (2002). HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Research and Human Retroviruses. 18: 567-576.
64. Manigart O, Courgnaud V, Sanou O, Vales D, Nagot N. Meda N, Delaporte E, Peeters M, Van de Perre P. (2004). HIV-1 superinfections in a cohort of commercial sex workers in Burkina Faso as assessed by an autologous heteroduplex mobility procedure. AIDS. 18: 1645-1651.
65. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, Birx DL. (1999). Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. Journal of Virology. 73: 4009-4018.
66. Mascola JR, Stiegler G, VanCott TC, Katinger R, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG. (2000). Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Medicine. 6: 207-210.
67. McCutchan FE, Hoelscher M, Tovanabutra S, Piyasirisilp S, Sanders-Buell E, Ramos G, Jagodzinski L, Polonis V, Maboko L, Mmbando D, Hoffmann O, Riedner G, von Sonnenburg F, Robb M, Birx DL. (2005). In-depth analysis of a heterosexually acquired human immunodeficiency virus type 1 superinfection: evolution, temporal fluctuation, and intercompartment dynamics from the seronegative window period through 30 months postinfection. Journal of Virology. 79: 1693-11704.
68. Mehandru S, Wrin T, Galovich J, Stiegler G, Vcelar B, Hurley A, Hogan C, Vasan S, Katinger H, Petropoulos CJ, Markowitz M. (2004). Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. Journal of Virology. 78: 14039-14042.
69. Mellquist JL, Becker-Pergola G, Gu J, Guay L, Himes L, Kataaha P, Mmiro F, Ndugwa C, Jackson JB, Eshleman SH. (1999). Dual transmission of subtype A and D HIV type 1 viruses from a Ugandan woman to her infant. AIDS Research and Human Retroviruses. 15: 217-221.
70. Moog C, Fleury HJ, Pellegrin I, Kirn A, Aubertin AM. (1997). Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. Journal of Virology. 71: 3734-3741.
71. Nguyen M, Pean P, Lopalco L, Nouhin J, Phoung V, Ly N, Vermisse P, Henin Y, Barre-Sinoussi F, Burastero SE, Reynes JM, Carcelain G, Pancino G. (2006). HIV-specific antibodies but not t-cell responses are associated with protection in seronegative partners of HIV-1-infected individuals in Cambodia. Journal of Acquired Immune Deficiency Syndrome. 42: 412-419.
72. Nowak P, Karlsson AC, Naver L, Bohlin AB, Piasek A, Sonnerborg A. (2002). The selection and evolution of viral quasispecies in HIV-1 infected children. HIV Medicine. 3: 1-11.
73. Pantaleo G, Koup RA. (2004). Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nature Medicine. 10: 806-810.
74. Pantophlet R, Burton DR. (2006). GP120: target for neutralizing HIV-1 antibodies. Annual Reviews in Immunology. 24: 739-769.
75. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR. (2001). Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. Journal of Virology. 75: 8340-8347.
76. Pernas M, Casado C, Fuentes R, Perez-Elias MJ, Lopez-Galindez C. (2006). A dual superinfection and recombination within HIV-1 subtype B 12 years after primoinfection. Journal of Acquired Immune Deficiency Syndrome. 42: 12-18.
77. Poss M, Martin HL, Kreiss JK, Granville L, Chohan B, Nyange P, Mandaliya K, Overbaugh J. (1995). Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1. Journal of Virology. 69: 8118-8122.
78. Quakkelaar ED, van Alphen FP, Boeser-Nunnink BD, van Nuenen AC, Pantophlet R, Schuitemaker H. (2007). Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies. Journal of Virology. 81: 8533-8542.
79. Ramos A, Hu DJ, Nguyen L, Phan KO, Vanichseni S, Promadej N, Choopanya K, Callahan M, Young NL, McNicholl J, Mastro TD, Folks TM, Subbarao S. (2002). Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users. Journal of Virology. 76: 7444-7452.
80. Richman DD, Wrin T, Little SJ, Petropoulos CJ. (2003). Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proceedings of the National Academy of Sciences of the United States of America. 100: 4144-4149.
81. Ritola K, Pilcher CD, Fiscus SA, Hoffman NG, Nelson JA, Kitrinos KM, Hicks CB, Eron JJ, Jr., Swanstrom R. (2004). Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. Journal of Virology. 78: 11208-11218.
82. Robertson CA, Mok JY, Froebel KS, Simmonds P, Burns SM, Marsden HS, Graham S. (1992). Maternal antibodies to gp120 V3 sequence do not correlate with protection against vertical transmission of human immunodeficiency virus. Journal of Infectious Diseases. 166: 704-709.
83. Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL, Derdeyn CA. (2007). Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. Journal of Virology. 81: 1350-1359.
84. Rong R, Gnanakaran S, Decker JM, Bibollet-Ruche F, Taylor J, Sfakianos JN, Mokili JL, Muldoon M, Mulenga J, Allen S, Hahn BH, Shaw GM, Blackwell JL, Korber BT, Hunter E, Derdeyn CA. (2007). Unique mutational patterns in the envelope alpha2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. Journal of Virology. 81: 5658-5668.
85. Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, Fischer M, Stiegler G, Katinger H, Olson WC, Weber R, Aceto L, Gunthard HF, Trkola A. (2005). Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. Journal of Virology. 79: 8454-8469.
86. Sagar M, Kirkegaard E, Lavreys L, Overbaugh J. (2006). Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection. AIDS Research and Human Retroviruses. 22: 430-437.
87. Sagar M, Kirkegaard E, Long EM, Celum C, Buchbinder S, Daar ES, Overbaugh J. (2004). Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes. Journal of Virology. 78: 7279-7283.
88. Sagar M, Wu X, Lee S, Overbaugh J. (2006). Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. Journal of Virology. 80: 9586-9598.
89. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP. (2002). The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. Journal of Virology. 76: 7293-7305.
90. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR. (2002). The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. Journal of Virology. 76: 7306-7321.
91. Scarlatti G, Albert J, Rossi P, Hodara V, Biraghi P, Muggiasca L, Fenyo EM. (1993). Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. Journal of Infectious Diseases. 168: 207-210.
92. Scarlatti G, Leitner T, Hodara V, Halapi E, Rossi P, Albert J, Fenyo EM. (1993). Neutralizing antibodies and viral characteristics in mother-to-child transmission of HIV-1. AIDS. 7(Suppl 2): S45-48.
93. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA. (1999). Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nature Medicine. 5: 204-210.
94. Skrabal K, Saragosti S, Labernardiere JL, Barin F, Clavel F, Mammano F. (2005). Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity. Journal of Virology. 79: 11848-11857.
95. Smith DM, Richman DD, Little SJ. (2005). HIV superinfection. Journal of Infectious Diseases. 192: 438-444.
96. Smith DM, Strain MC, Frost SD, Pillai SY, Wong JY, Wrin T, Liu Y. Petropolous CJ, Daar ES, Little SJ, Richman DD. (2006). Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology. 355: 1-5.
97. Smith DM, Wong JY, Hightower GK, Ignacio CC, Koelsch KK, Daar ES, Richman DD, Little SJ. (2004). Incidence of HIV superinfection following primary infection. JAMA. 292: 1177-1178.
98. Smith DM, Wong JK, Hightower GK, Ignacio CC, Koelsch KK, Petropoulos CJ, Richman DD, Little SJ. (2005). HIV drug resistance acquired through superinfection. AIDS. 19: 1251-1256.
99. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Gunthard M. (2005). Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nature Medicine. 11: 615-622.
100. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H. (1996). Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. Journal of Virology. 70: 1100-1108.
101. Tsui R, Herring BL, Barbour JD, Grant RM, Bacchetti P, Kral A, Edlin BR, Delwart EL. (2004). Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. Journal of Virology. 78: 94-103.
102. van der Kuyl AC, Kozaczynska K, van den Burg R, Zorgdrager F, Back N, Jurriaans S, Berkhout B, Reiss P, Cornelissen M. (2005). Triple HIV-1 infection. New England Journal of Medicine. 352: 2557-2559.
103. Van Rompay KK, Berardi CJ, Dillard-Telm S, Tarara RP, Canfield DR, Valverde CR, Montefiori DC, Cole KS, Montelaro RC, Miller CJ, Marthas ML. (1998). Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. Journal of Infectious Diseases. 177: 1247-1259.
104. Verhofstede C, Demecheleer E, De Cabooter N, Gaillard P, Mwanyumba F, Claeys P, Chohan V, Mandaliya K, Temmerman M, Plum J. (2003). Diversity of the human immunodeficiency virus type 1 (HIV-1) env sequence after vertical transmission in mother-child pairs infected with HIV-1 subtype A. Journal of Virology. 77: 3050-3057.
105. Watson A, Ranchalis J, Travis B, McClure J, Sutton W, Johnson PR, Hu SL, Haigwood NL. (1997). Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. Journal of Virology. 71: 284-290.
106. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. (2003). Antibody neutralization and escape by HIV-1. Nature. 422: 307-312.
107. Wolfs TF, Zwart G, Bakker M, Goudsmit J. (1992). HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology. 189: 103-110.
108. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, Kunstman KJ, Furtado MR, Munoz JL. (1992). Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science. 255: 1134-1137.
109. Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, Mbori-Ngacha D, Rainwater SM, Overbaugh J. (2006). Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. Journal of Virology. 80: 835-844.
110. Yang OO, Daar ES, Jamieson BD, Balamurugan A, Smith DM, Pitt JA, Petropoulos CJ, Richman DD, Little SJ, Brown AJ. (2005). Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains. Journal of Virology. 79: 860-868.
111. Yerly S, Jost S, Monnat M, Telenti A, Cavassini M, Chave JP, Kaiser L, Burgisser P, Perrin L. (2004). HIV-1 co/super-infection in intravenous drug users. AIDS. 13: 1413-1421.
112. Zhang H, Hoffmann F, He J, He X, Kankasa C, West JT, Mitchell CD, Ruprecht RM, Orti G, Wood C. (2006). Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease. Retrovirology. 3: 73.
113. Zhang H, Orti G, Du Q, He J, Kankasa C, Bliat G, Wood C. (2002). Phylogenetic and phenotypic analysis of HIV type 1 env gp120 in cases of subtype C mother-to-child transmission. AIDS Research and Human Retroviruses. 18: 1415-1423.
114. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD. (1993). Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science. 261: 1179-1181.
115. Zhu T, Wang N, Carr A, Nam DS, Moor-Jankowski R, Cooper DA, Ho DD. (1996). Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. Journal of Virology. 70: 3098-3107.
116. Zwick MB. (2005). The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring. AIDS. 19: 1725-1737.